University Of Michigan Rogel Cancer Center
Clinical trials sponsored by University Of Michigan Rogel Cancer Center, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can online tools boost genetic testing in families with hereditary cancer? Results expected Sep 2026 (estimated)
- New combo therapy aims to stop breast cancer return Results expected Oct 2026 (estimated)
- New needle probe aims to spot prostate cancer without extra tissue samples Results expected Oct 2026 (estimated)
- Shorter radiation may spare side effects for prostate cancer patients Results expected Nov 2026 (estimated)
- Can a simple blood test predict sarcoma recurrence? Results expected Nov 2026 (estimated)
-
Experimental combo for tough leukemia shows promise in early trial
Disease control Stopped earlyThis pilot study tested adding the targeted drug venetoclax to standard chemotherapy (FLAG or CLAG) for people with newly diagnosed secondary acute myeloid leukemia (sAML), a challenging blood cancer. The goal was to see if the combination could improve complete remission rates. …
Phase 2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Promising combo for rare lymphoma hits roadblock: trial ends early
Disease control Stopped earlyThis study tested a combination of two drugs, ixazomib and romidepsin, for people with a rare type of blood cancer called peripheral T-cell lymphoma that had returned or stopped responding to treatment. The trial was stopped early after enrolling only 11 participants, so the high…
Phase 1/2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy aims to keep advanced lung cancer in check
Disease control Stopped earlyThis study looked at whether a combination of two drugs, rucaparib and pembrolizumab, could help people with stage IV non-small cell lung cancer keep their cancer from growing after initial treatment. The study included 25 adults whose cancer had not gotten worse after standard c…
Phase 1/2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental combo shows promise for tough bile duct cancer
Disease control Stopped earlyThis study tested whether adding an experimental drug called CPI-613 (devimistat) to standard chemotherapy (gemcitabine plus cisplatin) could help people with advanced biliary tract cancer that cannot be removed by surgery. The trial had two parts: first, finding the safest dose …
Phase 1/2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Hot flash relief drug studied in breast cancer patients
Symptom relief Stopped earlyThis study tested fezolinetant, a drug that blocks a brain receptor involved in temperature control, to see if it reduces hot flashes and night sweats in women with breast cancer taking hormone therapy. Nine participants were enrolled before the trial was stopped early. The goal …
Phase 2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC